Independent Financial Information Made Easy
The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.
Open: 71.74 Close: 71.62 Change: -0.12
The game is changing. There is a new strategy to evaluate Intra-Cellular Therapies fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Intra-Cellular Therapies are: price, IntraCellular, Therapies, analyst, Bullish, Somewhat, Bearish, …
Intra-Cellular Therapies, Inc. focuses on the discovery, clinical development, and commercialization of small molecule drugs. The company offers CAPLYTA for schizophrenia and bipolar depression in adults. It is also developing Lumate.
Intra-Cellular Therapies (NASDAQ: ITCI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Bullish Indifferent Somewhat Bearish Bearish.
Intra-Cellular Therapies (NASDAQ: ITCI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings. These 4 analysts have an average price target of $81.0 versus the current price of Intra.29, implying upside. Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells. 39 analysts offering price forecasts for Intra-Cellular Therapies have a median target of 74.85, with a high estimate of 101.00 and a low estimate of 49.00. According to the current price, Intra.Therapies is 96.55% away from the 52.
"Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York."
This document will help you to evaluate Intra-Cellular Therapies without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Intra-Cellular Therapies are: price, IntraCellular, Therapies, analyst, Bullish, Somewhat, Bearish, and the most common words in the summary are: therapy, intracellular, inc, market, cell, stock, news, . One of the sentences in the summary was: Intra-Cellular Therapies (NASDAQ: ITCI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Bullish Indifferent Somewhat Bearish Bearish.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapy #intracellular #inc #market #cell #stock #news.
Read more →Open: 67.2 Close: 66.98 Change: -0.22
Read more →Open: 65.1 Close: 66.31 Change: 1.21
Read more →Open: 59.71 Close: 59.26 Change: -0.45
Read more →Open: 55.59 Close: 55.86 Change: 0.27
Read more →Open: 71.74 Close: 71.62 Change: -0.12
Read more →Open: 59.04 Close: 59.42 Change: 0.38
Read more →Open: 49.9 Close: 50.87 Change: 0.97
Read more →Open: 64.5 Close: 64.91 Change: 0.41
Read more →